{"composite_breakdown_label":"","computation_units":"","copyright":"","data_footnote":"","data_non_statistical":false,"data_notice_class":"","data_notice_heading":"","data_notice_text":"","data_show_map":false,"data_start_values":[{"field":"Type of vaccine","value":"Diphtheria, tetanus, and pertussis in children"},{"field":"Type of vaccine","value":"Pneumococcal disease in children"},{"field":"Type of vaccine","value":"Measles, mumps, and rubella in children"},{"field":"Type of vaccine","value":"Human papillomavirus (HPV) in adolescents"}],"embedded_feature_footer":"","embedded_feature_html":"","embedded_feature_tab_title":"","embedded_feature_title":"","embedded_feature_url":"","expected_disaggregations":[],"graph_annotations":[],"graph_limits":[],"graph_stacked_disaggregation":"","graph_title":"Proportion of the target population covered by all vaccines included in their national programme","graph_titles":[],"graph_type":"line","indicator_name":"Proportion of the target population covered by all vaccines included in their national programme","indicator_number":"3.b.1","national_geographical_coverage":"","page_content":"<b>Desired direction:</b> Increase","permalink":"","precision":[],"progress_status":"retroceso","reporting_status":"complete","sort":"","sources":[{"organisation":"Ministry of Health","periodicity":"Annual","url":"https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/S/sivamin","url_text":"Systematic Vaccination Statistics","logo":"/assets/img/fuentes/GE.png"}],"standalone":false,"tags":[],"indicador_disponible":"Proportion of the target population covered by all vaccines included in their national programme","objetivo_global":"3- Ensure healthy lives and promote well-being for all at all ages","meta_global":"3.b Support the research and development of vaccines and medicines for the communicable and non\u2011communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","definicion":"Proportion of the target population covered by all vaccines included in their national programme","formula":"\n$$PPV_{\\text{vaccine}}^{t} = \\frac{PV_{\\text{vaccine}}^{\\text{cohort}\\, t - c}}{P^{\\text{cohort}\\, t - c}} \\cdot 100$$\n\nwhere:\n\n$PV_{\\text{vaccine}}^{\\text{cohort}\\, t - c}=$ population vaccinated with the specified type of vaccine, \nbelonging to the cohort born in $t-c$\n\n$P^{\\text{cohort}\\, t - c}=$ total population of the cohort born in $t-c$\n\n${c}=$ interval of years that defines the specific cohort for each vaccine (c=1 or cohort born at t-1 for DPTa and VNC, c=5 for SRP and c=13 for VPH)\n","desagregacion":"Vaccine type: \n- booster vaccination against diphtheria, tetanus, and whooping cough in children (DPTa) \n- booster vaccination against pneumococcus in the pediatric population (VNC)  \n- second dose of the measles, mumps, and rubella vaccine in children (SRP) \n- second dose of the human papillomavirus (HPV) vaccine in adolescents \n\nSex\n","periodicidad":"Annual","observaciones":"\nThe results are obtained using the definitions proposed by the Vaccination Registry and \nProgram Report and agreed by the Public Health Commission in October 2017. Since then, \nvaccination coverage has been calculated by population birth cohorts. \n\nVaccines purchased in pharmacies or administered by the private health sector are not included.\n","texto_oceca":"<img src=\"/site/assets/img/oceca/ocecas_image.png\" style=\"width: 200px; float: left; margin-right: 10px;\" alt=\"Logo OCECAS\"> Indicator calculated using a methodology harmonised across the central statistical bodies of the autonomous communities","justificacion_global":"This indicator aims to measure access to vaccines, including the newly available or \nunderutilized vaccines, at the national level.\n\nIn the past decades all countries added numerous new and underutilised vaccines in \ntheir national immunization schedule and there are several vaccines under final stage of \ndevelopment to be introduced by 2030. For monitoring diseases control and impact of vaccines \nit is important to measure coverage from each vaccine in national immunization schedule. \nDirect measurement for proportion of population covered with all vaccines in the programme \nis only feasible if the country has a wellfunctioning national electronic immunization registry \nallowing coverage by cohort to be easily estimated. \n\nFollowing vaccines are measured:\n\n - Coverage of DTP containing vaccine (3rd dose): Percentage of surviving infants who \nreceived the 3 doses of diphtheria and tetanus toxoid with pertussis containing vaccine \nin a given year.\n\n - Coverage of Measles containing vaccine (2nd dose): Percentage of children who received \ntwo dose of measles containing vaccine according to nationally recommended schedule through \nroutine immunization services in a given year. \n\n - Coverage of Pneumococcal conjugate vaccine (last dose in the schedule): Percentage of \nsurviving infants who received the nationally recommended doses of pneumococcal conjugate \nvaccine in a given year. \n\n - Coverage of HPV vaccine (last dose in the schedule): Percentage of 15 years old girls \nwho received the recommended doses of HPV vaccine. Currently performance of the programme \nin the previous calendar year based on target age group is used. \n\nSource: United Nations Statistics Division\n","dato_global":"\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_DTP3&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proportion of the target population who received 3 doses of diphtheria-tetanus-pertussis (DTP3) vaccine (%) SH_ACS_DTP3</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_MCV2&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proportion of the target population who received measles-containing-vaccine second-dose (MCV2) (%) SH_ACS_MCV2</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_PCV3&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%) SH_ACS_PCV3</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_HPV&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\">Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%) SH_ACS_HPV</a> UNSTATS \n","comparabilidad":"The available indicator complies with United Nations metadata.","indicador_meta_enlace":"<a href=\"https://unstats.un.org/sdgs/metadata/files/Metadata-03-0b-01.pdf\">Metadata 3-b-1.pdf</a>","national_data_updated_date":"","national_metadata_updated_date":"","es":{"indicador_disponible":"Proportion of the target population covered by all vaccines included in their national programme","objetivo_global":"3- Ensure healthy lives and promote well-being for all at all ages","meta_global":"3.b Support the research and development of vaccines and medicines for the communicable and non\u2011communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","definicion":"Proporcio\u0301n de la poblacio\u0301n inmunizada con todas las vacunas incluidas en cada programa nacional","formula":"\n$$PPV_{\\text{vacuna}}^{t} = \\frac{PV_{\\text{vacuna}}^{\\text{cohorte}\\, t - c}}{P^{\\text{cohorte}\\, t - c}} \\cdot 100$$\n\ndonde:\n\n$PV_{\\text{vacuna}}^{\\text{cohorte}\\, t - c}=$ es la poblaci\u00f3n vacunada con el tipo de vacuna especificado, \nperteneciente a la cohorte nacida en $t-c$\n\n$P^{\\text{cohorte}\\, t - c}=$ es la poblaci\u00f3n total de la cohorte nacida en $t-c$\n\n${c}=$ el intervalo de a\u00f1os que define la cohorte espec\u00edfica para cada vacuna (c=1 o cohorte nacida en t-1 para DTPa y VNC, c=5 para SRP y c=13 para VPH)\n","desagregacion":"Tipo de vacuna \n","periodicidad":"Annual","observaciones":"\nLos resultados facilitados se obtienen utilizando las definiciones propuestas por la \nPonencia de Programa y Registro de Vacunaciones y acordadas por la Comisi\u00f3n de Salud \nP\u00fablica en octubre de 2017. Desde entonces, las coberturas de vacunaci\u00f3n se calculan \npor cohortes de nacimiento de la poblaci\u00f3n.\n\nNo se incluyen las vacunas adquiridas en oficinas de farmacia ni las \nadministradas por el sector sanitario privado.\n","texto_oceca":"<img src=\"/site/assets/img/oceca/ocecas_image.png\" style=\"width: 200px; float: left; margin-right: 10px;\" alt=\"Logo OCECAS\"> Indicator calculated using a methodology harmonised across the central statistical bodies of the autonomous communities","justificacion_global":"Este indicador tiene por objeto medir el acceso a las vacunas, incluidas las vacunas recientemente \ndisponibles o las que se utilizan de forma insuficiente, a nivel nacional.\n\nEn las \u00faltimas d\u00e9cadas, todos los pa\u00edses \nhan a\u00f1adido numerosas vacunas nuevas y que se utilizan de forma insuficiente a sus calendarios nacionales de \nvacunaci\u00f3n y hay varias vacunas en la fase final de desarrollo que se introducir\u00e1n de aqu\u00ed a 2030. Para supervisar el \ncontrol de enfermedades y el impacto de las vacunas, es importante medir la cobertura de cada vacuna del calendario nacional \nde vacunaci\u00f3n. La medici\u00f3n directa de la proporci\u00f3n de la poblaci\u00f3n cubierta con todas las vacunas del programa solo es posible \nsi el pa\u00eds cuenta con un registro electr\u00f3nico nacional de vacunaci\u00f3n que funcione bien y permita estimar \nf\u00e1cilmente la cobertura por cohorte.\n\nSe miden las siguientes vacunas:\n\n - Cobertura de la vacuna DTP (tercera dosis): porcentaje de lactantes supervivientes que recibieron \nlas 3 dosis de la vacuna contra la difteria, el t\u00e9tanos y la tos ferina en un a\u00f1o determinado.\n\n - Cobertura de la vacuna contra el sarampi\u00f3n (segunda dosis): porcentaje de ni\u00f1os que recibieron dos dosis de la vacuna contra el sarampi\u00f3n seg\u00fan el calendario recomendado a nivel nacional a trav\u00e9s de los servicios de vacunaci\u00f3n de rutina\n en un a\u00f1o determinado.\n\n - Cobertura de la vacuna antineumoc\u00f3cica conjugada (\u00faltima dosis del calendario): porcentaje de lactantes \nsupervivientes que recibieron las dosis de vacuna antineumoc\u00f3cica conjugada recomendadas a nivel nacional en un a\u00f1o determinado.\n\n - Cobertura de la vacuna contra el VPH (\u00faltima dosis del calendario): porcentaje de ni\u00f1as de 15 a\u00f1os que recibieron \nlas dosis recomendadas de la vacuna contra el VPH. Actualmente se utiliza el desempe\u00f1o del programa en el a\u00f1o \ncalendario anterior en funci\u00f3n del grupo de edad objetivo.\n\nFuente: Divisi\u00f3n de Estad\u00edsticas de las Naciones Unidas\n","dato_global":"\n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_DTP3&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proporci\u00f3n de la poblaci\u00f3n objetivo que recibi\u00f3 3 dosis de la vacuna contra la difteria, el t\u00e9tanos y la tos ferina (DTP3) (%) SH_ACS_DTP3</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_MCV2&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proporci\u00f3n de la poblaci\u00f3n objetivo que recibi\u00f3 la segunda dosis de la vacuna contra el sarampi\u00f3n (MCV2) (%) SH_ACS_MCV2</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_PCV3&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\"> Proporci\u00f3n de la poblaci\u00f3n objetivo que recibi\u00f3 una tercera dosis de la vacuna antineumoc\u00f3cica conjugada (PCV3) (%) SH_ACS_PCV3</a> UNSTATS \n\n<a href=\"https://unstats.un.org/sdgs/dataportal/analytics/SingleSeries?indicators=3.b.1&seriesCode=SH_ACS_HPV&areaCode=  276,40,56,100,196,191,208,703,705,724,233,246,250,300,528,348,372,380,428,440,442,470,616,620,203,642,752,1,202,14,17,18,11,747,15,145,62,143,34,753,30,35,419,29,13,5,9,54,57,61,53,513,150,21,432,199,722&period=3&table=Total\">Proporci\u00f3n de la poblaci\u00f3n objetivo que recibi\u00f3 la dosis final de la vacuna contra el virus del papiloma humano (VPH) (%) SH_ACS_HPV</a> UNSTATS \n","comparabilidad":"El indicador disponible cumple con los metadatos de Naciones Unidas.","indicador_meta_enlace":"<a href=\"https://unstats.un.org/sdgs/metadata/files/Metadata-03-0b-01.pdf\">Metadatos 3-b-1.pdf</a> (solo en ingl\u00e9s)"},"target_number":"3.b","goal_number":"3","indicator_sort_order":"03-0b-01","informacion_interes":null}